ArriVent Biopharma
Signal active
Organization
Contact Information
Overview
ArriVent is a biopharmaceutical company developing pharmaceutical products to cure presently untreatable cancer.
About
Industries
Biotechnology, Life Science, Pharmaceutical
Founded
2021
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
ArriVent Biopharma headquartered in United States, North America, operates in the Biotechnology, Life Science, Pharmaceutical sector. The company focuses on Biotechnology and has secured $11.0B in funding across 36 round(s). With a team of 11-50 employees, ArriVent Biopharma is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - ArriVent Biopharma, raised $155.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
3
Investors
17
Lead Investors
0
Total Funding Amount
$305.0M
Details
3
ArriVent Biopharma has raised a total of $305.0M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2021 | Early Stage Venture | 81.0M | ||
| 2022 | Early Stage Venture | 69.0M | ||
| 2022 | Early Stage Venture | 155.0M |
Investors
ArriVent Biopharma is funded by 34 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| John Yetimoglu | - | FUNDING ROUND - John Yetimoglu | 155.0M |
| Infinitum Partners | - | FUNDING ROUND - Infinitum Partners | 155.0M |
| ArriVent Biopharma | - | FUNDING ROUND - ArriVent Biopharma | 155.0M |
| HBM Partners | - | FUNDING ROUND - HBM Partners | 155.0M |
Recent Activity
There is no recent news or activity for this profile.